Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.

Casarejos MJ, Perucho J, Gomez A, Muñoz MP, Fernandez-Estevez M, Sagredo O, Fernandez Ruiz J, Guzman M, de Yebenes JG, Mena MA.

J Alzheimers Dis. 2013;35(3):525-39. doi: 10.3233/JAD-130050.

PMID:
23478312
2.

Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.

Rodríguez-Navarro JA, Rodríguez L, Casarejos MJ, Solano RM, Gómez A, Perucho J, Cuervo AM, García de Yébenes J, Mena MA.

Neurobiol Dis. 2010 Sep;39(3):423-38. doi: 10.1016/j.nbd.2010.05.014.

PMID:
20546895
3.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w.

4.

Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.

Menéndez J, Rodríguez-Navarro JA, Solano RM, Casarejos MJ, Rodal I, Guerrero R, Sánchez MP, Avila J, Mena MA, de Yébenes JG.

Hum Mol Genet. 2006 Jul 1;15(13):2045-58.

5.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007.

PMID:
18490011
6.

Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice.

Rodríguez-Navarro JA, Gómez A, Rodal I, Perucho J, Martinez A, Furió V, Ampuero I, Casarejos MJ, Solano RM, de Yébenes JG, Mena MA.

Hum Mol Genet. 2008 Oct 15;17(20):3128-43. doi: 10.1093/hmg/ddn210.

7.

Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9980-5.

8.

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH.

J Neurosci. 2005 Nov 16;25(46):10637-47.

9.

Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.

Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM.

J Neurosci. 2004 May 12;24(19):4657-67.

10.

Hyperexcitability and epileptic seizures in a model of frontotemporal dementia.

García-Cabrero AM, Guerrero-López R, Giráldez BG, Llorens-Martín M, Avila J, Serratosa JM, Sánchez MP.

Neurobiol Dis. 2013 Oct;58:200-8. doi: 10.1016/j.nbd.2013.06.005.

PMID:
23774255
11.

PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation.

Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA.

J Neurosci. 2003 Oct 1;23(26):8989-9003.

12.

Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice.

Umeda T, Yamashita T, Kimura T, Ohnishi K, Takuma H, Ozeki T, Takashima A, Tomiyama T, Mori H.

Am J Pathol. 2013 Jul;183(1):211-25. doi: 10.1016/j.ajpath.2013.03.015.

PMID:
23680655
13.

A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.

Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C.

Br J Pharmacol. 2015 Jul;172(14):3579-95. doi: 10.1111/bph.13159.

14.

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jové M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M.

Hum Mol Genet. 2014 Jul 15;23(14):3716-32. doi: 10.1093/hmg/ddu080.

15.

Impaired glutamate transport in a mouse model of tau pathology in astrocytes.

Dabir DV, Robinson MB, Swanson E, Zhang B, Trojanowski JQ, Lee VM, Forman MS.

J Neurosci. 2006 Jan 11;26(2):644-54.

16.

Effects of alpha-tocopherol on an animal model of tauopathies.

Nakashima H, Ishihara T, Yokota O, Terada S, Trojanowski JQ, Lee VM, Kuroda S.

Free Radic Biol Med. 2004 Jul 15;37(2):176-86.

PMID:
15203189
17.

Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model.

Paban V, Manrique C, Filali M, Maunoir-Regimbal S, Fauvelle F, Alescio-Lautier B.

Neuropharmacology. 2014 Jan;76 Pt A:68-79. doi: 10.1016/j.neuropharm.2013.06.033.

PMID:
23891615
18.

[Animal models of tauopathies].

Higuchi M.

Rinsho Shinkeigaku. 2006 Nov;46(11):928-30. Japanese.

PMID:
17432223
19.

Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.

Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ, de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, van Leuven F, Lucassen PJ.

J Neurosci. 2006 Mar 29;26(13):3514-23.

20.

The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.

Curr Pharm Des. 2011;17(5):489-507. Review.

PMID:
21375482
Items per page

Supplemental Content

Support Center